October 9 is the day circled on the calendar for one of the year’s most closely watched cancer-drug decisions: whether an immunotherapy added to chemotherapy after surgery becomes a new standard for a specific, aggressive form of colon cancer.
The Food and Drug Administration is due to decide on applications for atezolizumab, an immune checkpoint inhibitor, used alongside a standard chemotherapy regimen in patients with stage III colon cancer whose tumours carry a particular genetic signature — known as mismatch repair-deficient, or MSI-high — that makes them unusually responsive to immunotherapy. The applications received Priority Review, the FDA’s faster track.
The evidence behind the filing comes from the phase 3 ATOMIC trial, which enrolled 712 patients. Adding the immunotherapy to chemotherapy cut the risk of the cancer returning or death by half compared with chemotherapy alone, according to the study’s results. After a median follow-up of about 41 months, 86 percent of patients on the combination remained disease-free at three years, versus 76 percent on chemotherapy alone.
That ten-point gap matters because stage III colon cancer sits on a knife edge: surgery plus chemotherapy cures many patients, but those whose cancer returns face far grimmer options. A treatment that prevents recurrence rather than chasing it later is the field’s most valuable currency.
The FDA’s deadline does not guarantee a verdict on the day, and regulators can extend reviews. But with priority status and positive phase 3 data in hand, oncologists treating this patient group are watching October 9 closely. Watch this space.
Related reading: Gut Bacteria May Reveal How Fast the Brain Is Aging, UCLA Study Suggests · Drug-Resistant Candida Auris Cases More Than Doubled in Two Years, CDC Data Show · CDC Flags a Sharp Rise in a Rare Brain Fungus With a Grim Fatality Rate
